The potential role of IL-33/ST2 signaling in fibrotic diseases
The DOI matches its Crossref record; 16 of the 16 references it cites were found in a registry or an index.
Abstract
IL-33, a new member of the IL-1F, is widely expressed throughout the body and can be up-regulated by stimulation with proinflammatory factors. It has been identified as a functional ligand for the plasma membrane receptor complex that is a heterodimer consisting of membrane-bound ST2L, which is a member of the IL-1R family, and IL-1RAcP. IL-33 is crucial for the induction of Th2 immune responses. Additionally, under other circumstances, it can also act as an endogenous danger signal. Recently, many studies have demonstrated that IL-33 may be related to the development and progression of fibrotic diseases. It has proinflammatory effects in some fibrotic diseases but has anti-inflammatory effects in others. In this review, the biologic characteristics of IL-33 and the role of the IL-33/ST2 signaling pathway in various fibrotic diseases will be discussed. We hope this overview will provide new insights for the treatment of these diseases.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Liver fibrosis – from bench to bedside
Friedman, S. L. (2003) · Journal of Hepatology · doi:10.1016/s0168-8278(02)00429-4 · Cited by 1,780
Moussion, C., Ortega, N., & Girard, J.-P. (2008) · PLoS ONE · doi:10.1371/journal.pone.0003331 · Cited by 1,179
Carriere, V., Roussel, L., Ortega, N., Lacorre, D.-A., Americh, L., Aguilar, L., Bouche, G., & Girard, J.-P. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0606854104 · Cited by 966 · cited 1×
“This heterochromatin-binding motif is associated with the transcriptional regulatory properties of IL-33 [4].”
BackgroundMechanisms of hepatic fibrogenesis
Lee, U. E., & Friedman, S. L. (2011) · Best Practice & Research Clinical Gastroenterology · doi:10.1016/j.bpg.2011.02.005 · Cited by 923
The IL-1-like cytokine IL-33 is inactivated after maturation by caspase-1
Cayrol, C., & Girard, J.-P. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0812690106 · Cited by 707 · cited 2×
“Furthermore, Cayrol and Girard [27] found that flIL-33 is active and that processing by caspase-1 results in IL-33 inactivation.”
BackgroundInterleukin-33-Dependent Innate Lymphoid Cells Mediate Hepatic Fibrosis
Mchedlidze, T., Waldner, M., Zopf, S., Walker, J., Rankin, A. L., Schuchmann, M., Voehringer, D., McKenzie, A. N. J., Neurath, M. F., Pflanz, S., et al. (2013) · Immunity · doi:10.1016/j.immuni.2013.07.018 · Cited by 502
Role of IL-33 in inflammation and disease
Miller, A. M. (2011) · Journal of Inflammation · doi:10.1186/1476-9255-8-22 · Cited by 481
Mi, S., Li, Z., Yang, H.-Z., Liu, H., Wang, J.-P., Ma, Y.-G., Wang, X.-X., Liu, H.-Z., Sun, W., & Hu, Z.-W. (2011) · The Journal of Immunology · doi:10.4049/jimmunol.1004081 · Cited by 370
Blockade of IL-6 Trans Signaling Attenuates Pulmonary Fibrosis
Le, T.-T. T., Karmouty-Quintana, H., Melicoff, E., Le, T.-T. T., Weng, T., Chen, N.-Y., Pedroza, M., Zhou, Y., Davies, J., Philip, K., et al. (2014) · The Journal of Immunology · doi:10.4049/jimmunol.1302470 · Cited by 299
Cardilo‐Reis, L., Gruber, S., Schreier, S. M., Drechsler, M., Papac‐Milicevic, N., Weber, C., Wagner, O., Stangl, H., Soehnlein, O., & Binder, C. J. (2012) · EMBO Molecular Medicine · doi:10.1002/emmm.201201374 · Cited by 292 · cited 8×
“This indicates that IL-33 induces skin fibrosis in an IL-13-dependent and IL-33R-dependent manner [85].”
BackgroundInfluential
Cited by
Biomaterials: Foreign Bodies or Tuners for the Immune Response?
Mariani, E., Lisignoli, G., Borzì, R. M., & Pulsatelli, L. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20030636 · Cited by 706
“The emerging links between IL-33 and fibrotic disorders [332,333] might suggest that the release of IL-33 at the biomaterial implantation site may induce collagen deposition.”
BackgroundThe IL-1 cytokine family and its role in inflammation and fibrosis in the lung
Borthwick, L. A. (2016) · Seminars in Immunopathology · doi:10.1007/s00281-016-0559-z · Cited by 294
Tosello‐Trampont, A., Krueger, P., Narayanan, S., Landes, S. G., Leitinger, N., & Hahn, Y. S. (2016) · Hepatology · doi:10.1002/hep.28389 · Cited by 142
“However, in fibrotic livers, expression of Il33 is elevated, indicating an active role for IL-33 in the initiation of, or response to, fibrosis.((31)) The local excess of IL-33 can be released into the blood of patients undergoing liver failure and has significant impact on liverresident and distal immune cell populat…”
BackgroundYang, M., Song, L., Wang, L., Yukht, A., Ruther, H., Li, F., Qin, M., Ghiasi, H., Sharifi, B. G., & Shah, P. K. (2018) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2018.05.061 · Cited by 73
“IL-33 is a highly fibrogenic cytokine (67), and it induces M2 polarization of macrophages as well as promotion of lung fibrosis (68,69).”
Background
Metadata
- Authors
- Gao, Q., Li, Y., & Li, M.
- Venue
- Journal of Leukocyte Biology
- Publisher
- Oxford University Press (OUP)
- Published
- 2015-04-16
- Volume
- 98
- Issue
- 1
- Pages
- 15-22
- ISSN
- 0741-5400 (ISSN-L)
- 1938-3673
- OpenAlex
- W2016787193
- Cited by
- 50
- References
- 16
- FWCI
- 2.75
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The potential role of IL-33/ST2 signaling in fibrotic diseases. https://app.cochat.ai/papers/10.1189/jlb.3ru0115-012r
- The paper
- Gao, Q., Li, Y., & Li, M. (2015). The potential role of IL-33/ST2 signaling in fibrotic diseases. Journal of Leukocyte Biology. https://doi.org/10.1189/jlb.3ru0115-012r
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.